These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38236563)

  • 1. Comment on: Anti-Coagulant Treatment of Cancer-Associated Thrombosis in Frail Patients: Impact of Frailties on the Management of Drug-Drug Interactions.
    Van der Linden L; Vanassche T; Van Aelst L; Verhamme P
    Clin Pharmacokinet; 2024 Mar; 63(3):395-396. PubMed ID: 38236563
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-coagulant Treatment of Cancer-Associated Thrombosis in Frail Patients: Impact of Frailties on the Management of Drug-Drug Interactions.
    Grange C; Rioufol C; Souquet PJ; Assaad S
    Clin Pharmacokinet; 2023 Nov; 62(11):1523-1531. PubMed ID: 37824026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The role of direct oral anticoagulants in the management of cancer-associated thrombosis in 2020].
    Auditeau C; Talbot A; Blandinières A; Smadja DM; Gendron N
    Bull Cancer; 2020 May; 107(5):574-585. PubMed ID: 32252973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frailty and Co-Prescribing of Potentially Interacting Drugs in New Users of Warfarin.
    Hauta-Aho M; Teperi S; Korhonen MJ; Bell JS; Farinola N; Johns S; Shakib S; Huupponen R
    Drugs Aging; 2020 May; 37(5):373-382. PubMed ID: 32147805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comment on: Role of anticoagulation in the management of tumor thrombus: A 10-year single-center experience.
    Nadeem B; Azhar M; Usman M
    Pediatr Blood Cancer; 2022 Nov; 69(11):e29692. PubMed ID: 35452166
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: Clinical consequences.
    Bellesoeur A; Thomas-Schoemann A; Allard M; Smadja D; Vidal M; Alexandre J; Goldwasser F; Blanchet B
    Crit Rev Oncol Hematol; 2018 Sep; 129():102-112. PubMed ID: 30097228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of frailty on anticoagulant prescription and clinical outcomes after 1-year follow-up in hospitalised older patients with atrial fibrillation.
    Gullón A; Formiga F; Díez-Manglano J; Mostaza JM; Cepeda JM; Pose A; Castiella J; Suárez-Fernández C;
    Intern Emerg Med; 2019 Jan; 14(1):59-69. PubMed ID: 30191535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH.
    Samuelson Bannow BT; Lee A; Khorana AA; Zwicker JI; Noble S; Ay C; Carrier M
    J Thromb Haemost; 2018 Jun; 16(6):1246-1249. PubMed ID: 29737593
    [No Abstract]   [Full Text] [Related]  

  • 9. The efficacy and safety of DOACs versus LMWH for cancer-associated thrombosis: A systematic review and meta-analysis.
    Tao DL; Olson SR; DeLoughery TG; Shatzel JJ
    Eur J Haematol; 2020 Sep; 105(3):360-362. PubMed ID: 32441350
    [No Abstract]   [Full Text] [Related]  

  • 10. Mechanism and management of cancer-associated thrombosis.
    Mukai M; Oka T
    J Cardiol; 2018 Aug; 72(2):89-93. PubMed ID: 29588087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complexity and clinical significance of drug-drug interactions (DDIs) in oncology: challenging issues in the care of patients regarding cancer-associated thrombosis (CAT).
    Tsoukalas N; Brito-Dellan N; Font C; Butler T; Rojas-Hernandez CM; Butler T; Escalante C;
    Support Care Cancer; 2022 Oct; 30(10):8559-8573. PubMed ID: 35932318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus.
    Carrier M; Blais N; Crowther M; Kavan P; Le Gal G; Moodley O; Shivakumar S; Tagalakis V; Wu C; Lee AYY
    Curr Oncol; 2018 Oct; 25(5):329-337. PubMed ID: 30464682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Not Available].
    Guschmann M
    Hamostaseologie; 2018 Feb; 38(1):60-65. PubMed ID: 29536485
    [No Abstract]   [Full Text] [Related]  

  • 14. Anticoagulants in thrombosis and cancer: the missing link.
    Mousa SA
    Semin Thromb Hemost; 2002 Feb; 28(1):45-52. PubMed ID: 11885025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting clotting proteins in cancer therapy - progress and challenges.
    Ruf W; Rothmeier AS; Graf C
    Thromb Res; 2016 Apr; 140 Suppl 1(Suppl 1):S1-7. PubMed ID: 27067961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The changing landscape of anticoagulation in cancer-associated thrombosis.
    Lee AYY
    Blood Adv; 2020 Mar; 4(5):969. PubMed ID: 32150614
    [No Abstract]   [Full Text] [Related]  

  • 17. Pathophysiology and management of thrombosis in cancer: 150 years of progress.
    Soff GA
    J Thromb Thrombolysis; 2013 Apr; 35(3):346-51. PubMed ID: 23440574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biology of frailty: Implications for clinical pharmacology and drug therapy in frail older people.
    Hilmer SN; Wu H; Zhang M
    Mech Ageing Dev; 2019 Jul; 181():22-28. PubMed ID: 31125572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose apixaban in extended treatment of cancer-associated thrombosis: Less is more?
    Barca-Hernando M; Marin-Romero S; Jara-Palomares L
    J Thromb Haemost; 2022 May; 20(5):1070-1072. PubMed ID: 35445577
    [No Abstract]   [Full Text] [Related]  

  • 20. Advances in the Management of Cancer-Associated Thrombosis.
    Dhami SPS; Patmore S; O'Sullivan JM
    Semin Thromb Hemost; 2021 Mar; 47(2):139-149. PubMed ID: 33636745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.